Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibition

25 Sept 2018

Abstract excerpt

Hypertrophic cardiomyopathies (HCM) result from distinct single-point mutations in sarcomeric proteins that lead to muscle hypercontractility. While different models account for a pathological increase in the power output, clear understanding of the molecular basis of dysfunction in HCM is the mandatory next step to improve current treatments. Here, we present an optimized quasi-atomic model of the sequestered...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiomyopathy and Myosin Studies
Share to Cardiovascular Effects of Exercise
Share to Cardiovascular Function and Risk Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30275503
DOI: 10.1038/s41467-018-06191-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibitionPMID 30275503Read ↗

Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibitionSemantic proximity Read ↗

Biophysical properties of human β-cardiac myosin with converter mutations that cause hypertrophic cardiomyopathySemantic proximity Read ↗

Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases.Semantic proximity Read ↗

Hypertrophic cardiomyopathy ß-cardiac myosin mutation (P710R) leads to hypercontractility by disrupting super-relaxed stateSemantic proximity Read ↗

Biophysical properties of human β-cardiac myosin with converter mutations that cause hypertrophic cardiomyopathySemantic proximity Read ↗

The hypertrophic cardiomyopathy mutation G768R makes cardiac myosin a high duty ratio motorSemantic proximity Read ↗

Beyond the myosin mesa: a potential unifying hypothesis on the underlying molecular basis of hyper-contractility caused by a majority of hypertrophic cardiomyopathy mutationsSemantic proximity Read ↗

Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers.Semantic proximity Read ↗

Mutations in the catalytic domain of human β-cardiac myosin that cause early onset hypertrophic cardiomyopathy significantly increase the fundamental parameters that determine ensemble force and velocitySemantic proximity Read ↗

Molecular mechanisms of cardiomyopathy phenotypes associated with myosin light chain mutations.Semantic proximity Read ↗

Incomplete-penetrant hypertrophic cardiomyopathy MYH7 G256E mutation causes hypercontractility and elevated mitochondrial respiration.Semantic proximity Read ↗

Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.